The three selected TAAs, Survivin, Mammaglobin-A, and HER2, were chosen for their known over-expression in BC (38–40) and for their ability to evoke functional T-cell responses, measured by IFN-γ ELISpot assays, in BC patients affected by a locally-advanced tumors (24). The gene discussed is ERBB2; the disease is breast cancer.